Switching from semaglutide to tirzepatide can offer major benefits like enhanced weight loss, improved blood sugar control, and a more potent dual-action mechanism
Whether this applies to humans is not established, but both carry a FDA boxed warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
Compared with lixisenatide, exenatide twice daily, liraglutide, albiglutide and dulaglutide, semaglutide is associated with highest nausea and vomiting rates, yet also with highest rates of improvement in glycemic control and weight loss (132)
Weight loss medication vials typically contain one months worth of medication
The actual amounts were 29% to 39% higher than labeled, meaning people could be taking much more of the drug than they intended to take which poses serious health risks